Atracurium besylate (Standard)
Atracurium (besylate) (Standard) is the analytical standard of Atracurium (besylate). This product is intended for research and analytical applications. Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation.
For research use only. We do not sell to patients.
- Purity: 0%
- CAS No.: 64228-81-5
- Formula: C₆₅H₈₂N₂O₁₈S₂
- Molecular Weight:1243.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-B0292A
Atracurium besylate
-
HY-12151
NS 1738
-
HY-14824
Sofiniclin
-
HY-B0379A
Adiphenine hydrochloride
-
HY-10019
Varenicline
-
HY-12560A
PNU-282987
-
HY-14564A
GTS-21 dihydrochloride
-
HY-N0175
Cytisinicline
-
HY-12560D
PNU-282987 S enantiomer free base
-
HY-B0118A
Vecuronium bromide
-
HY-12152
PNU-120596
-
HY-B0979
Lobeline hydrochloride
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 64228-81-5
-
Molecular Weight 1243.48
-
Formula C₆₅H₈₂N₂O₁₈S₂
-
SMILES
O=S(C1=CC=CC=C1)([O-])=O.O=C(OCCCCCOC(CC[N+]2(C)C(CC3=CC=C(OC)C(OC)=C3)C4=C(C=C(OC)C(OC)=C4)CC2)=O)CC[N+]5(C)C(CC6=CC=C(OC)C(OC)=C6)C7=C(C=C(OC)C(OC)=C7)CC5.O=S(C8=CC=CC=C8)([O-])=O
-
Synonyms
BW-33A (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. [Content Brief]
[2]. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. [Content Brief]
[3]. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. [Content Brief]
[4]. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. [Content Brief]
[5]. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Atracurium besylate (Standard) Related Classifications
HY-B0292AR Related Classifications
Powered by Bioz